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ABSTRACT
Of the over 200 identified mammalian microRNAs
(miRNAs), only a few have known biological activity.
TogainabetterunderstandingoftherolethatmiRNAs
play in specific cellular pathways, we utilized anti-
sense molecules to inhibit miRNA activity. We used
miRNAinhibitorstargetingmiR-23,21,15a,16and19a
to test efficacy of antisense molecules in reducing
miRNA activity on reporter genes bearing miRNA-
binding sites. The miRNA inhibitors de-repressed
reporter gene activity when a miRNA-binding site
was cloned into its 30-untranslated region. We
employed a library of miRNA inhibitors to screen for
miRNAinvolvedincellgrowthandapoptosis.InHeLa
cells,wefoundthatinhibitionofmiR-95,124,125,133,
134,144,150,152,187,190,191,192,193,204,211,218,
220,296and299causedadecreaseincellgrowthand
that inhibition of miR-21 and miR-24 had a profound
increase in cell growth. On the other hand, inhibition
of miR-7, 19a, 23, 24, 134, 140, 150, 192 and 193 down-
regulatedcellgrowth,andmiR-107,132,155,181,191,
194, 203, 215 and 301 increased cell growth in lung
carcinoma cells, A549. We also identified miRNA that
when inhibited increased the level of apoptosis (miR-
1d, 7, 148, 204, 210, 216 and 296) and one miRNA that
decreased apoptosis (miR-214) in HeLa cells. From
these screens, we conclude that miRNA-mediated
regulation has a complexity of cellular outcomes
and that miRNAs can be mediators of regulation of
cell growth and apoptosis pathways.
INTRODUCTION
Cellular microRNAs (miRNAs) are a class of 17–24 base
single-stranded RNA molecules that are expressed in cells
from plants to animals (1). MiRNAs are expressed as long
precursor RNAs that get processed by a cellular nuclease,
Drosha, before being transported by an Exportin-5-
dependent mechanism into the cytoplasm (2). Once in the
cytoplasm miRNAs are cleaved further by the enzyme
DICER (3,4) and the resulting 17–24 nt miRNAs associate
with a cellular complex that is at least similar to the RNA-
induced silencing complex that participates in RNA interfer-
ence (5). The complex-bound single-stranded miRNA guides
the complex to mRNAs with sequences that are at least par-
tially complementary to the miRNA. The translation of the
bound mRNA is inhibited by a mechanism that is not fully
understood (6).
MiRNAs are a very prevalent class of cellular RNAs, but
because they have only recently been identiﬁed, very few
miRNAs have known cellular functions. Currently, the
best understood miRNA, lin-4, was ﬁrst identiﬁed in
Caenorhabditis elegans [reviewed in(7,8)].Researchrevealed
that lin-4 accumulates during the ﬁrst and second larval stages
and triggers passage to the third larval stage by repressing the
translation of at least two genes, lin-14 and lin-28 (9). The
activity of lin-4 depends on the partial homology of the
miRNA to speciﬁc regions of the 30-untranslated regions
(30-UTRs) of the lin-14 and lin-28 mRNAs (9,10). A second
miRNA, let-7 accumulates during C.elegans larval develop-
ment and triggers passage from late larval to adult cell fates
(11,12). A few other miRNAs, such as bantam and miR-14,
have at least partial deﬁned roles in cells (13,14). Currently,
only a few mammalian miRNAs have been shown to have a
deﬁned role in a biological process while associations have
implicated others. In one example, the mammalian miRNA,
miR-181, was found to be speciﬁcally expressed and dynam-
ically regulated in hematopoietic cells, and its expression in
hematopoietic stem/progenitor cells increased the fraction of
B-cells in both tissue culture and adult mice (15).
Four reports have correlated aberrant miRNA expression
with cancer, cancer-associated genomic regions and fragile
sites in chromosomes. First, loss at 13q14 constitutes
the most frequent chromosomal abnormality in chronic
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doi:10.1093/nar/gki200lymphocytic leukemia (CLL), suggesting the involvement
of one or more tumor suppressor genes at this locus.
Although several groups had performed detailed genetic
analyses, including extensive loss of heterozygosity, mutation
andexpression studies,noconsistentinvolvementofanyofthe
genes with open reading frames located in the deleted region
wasdemonstrated.Interestingly,thegenesformiR-15andmiR-
16 are located at this locus and appear to be deleted in the
majority of B-CLL cases (16). Second, studies of miRNA
expression in colonic adenocarcinoma and normal mucosa
were used to identify potential links between miRNA expres-
sion/maturation and cancer (17). Out of 28 miRNAs identiﬁed
in human colorectal mucosa, two (miR-143 and miR-145)
proved to be signiﬁcantly down-regulated in 12 adenocar-
cinoma samples compared with matched, normal tissues.
Third,thehumanBICRNAiselevatedinchildrenwithLymph-
oma. Metzler and co-workers (18) indicate that the BIC gene
encodes miR-155. Using PCR, they demonstrate that the
expression of the precursor of miR-155 is found in children
with Burkitt Lymphoma, but not patients with pediatric leuk-
emia. Fourth, in a recent study, the chromosomal locations of
186 miRNA genes were mapped and compared with the loca-
tion of non-random genetic alterations (19). Over 52% of the
miRNA genes analyzed are in cancer-associated genomic
regions or in fragile sites. This study also found that several
miRNAs located in deleted regions are expressed at low levels
in cancer samples.
As stated above, miRNA bind to mRNA targets and
inhibit translation by a currently unknown mechanism.
While several publications predict target genes for Drosophila
and human miRNA (19,20), only a few have been conﬁrmed
using reporter genes. In the most comprehensive study to date,
Lewis et al. (19) predicted mRNA targets for human miRNA
and used a reporter construct with the 30-UTRs of 16 target
genes to conﬁrm target sites for 8 miRNAs. The system of
transfecting miRNA or miRNA expression vectors and
reporter constructs with predicted miRNA-binding sites offers
the most straightforward method for conﬁrming target sites;
however, it does not demonstrate biological signiﬁcance.
In light of the need to identify miRNA targets and their cor-
responding function, miRNA inhibitors and miRNA expres-
sion systems will also be valuable (15,21–23). MiRNA
inhibitors have also recently been proven to be valuable in
understanding miRNA function (22–24). Not only were
the miRNA inhibitors shown to be active in human cells,
but the let-7 antisense molecules were injected into C.elegans
and found to induce a let-7 loss-of-function phenotype
(24), validating the use of these molecules for miRNA
inhibition.
We used a library of miRNA inhibitors in functional screen-
ing assays to identify miRNAs that affect cell proliferation and
apoptosis. Before screening, we validated the efﬁcacy of the
miRNA inhibitors using a luciferase reporter bearing miRNA
target sequences cloned into its 30-UTR. In each case, the
miRNA inhibitors inhibited the repression of the endogenous
miRNA on the reporter gene. Screening our library of miRNA
inhibitorstargetingover 90 human miRNAsresulted inseveral
interesting observations. First, the hits identiﬁed for cell
growth were not the same between different cell lines. Second,
both increases and decreases in cell number and apoptosis
were identiﬁed. Our results indicate that miRNA-mediated
gene regulatory pathways are complex and have roles in
important biological processes.
MATERIALS AND METHODS
Reporter vectors and DNA constructs
To generate reporter vectors bearing miRNA-binding sites, we
generated direct match miRNA target sites and cloned these
inserts into the multiple cloning sites in the luciferase reporter
vector described in Figure 1A. The sense and antisense strands
of the oligonucleotides were annealed by adding 2 mg of each
oligonucleotide to 46 ml of annealing solution (100 mM
potassium acetate, 30 mM HEPES-KOH, pH 7.4 and 2 mM
Magnesium acetate) and incubated at 90 C for 5 min and then
at 37 C for 1 h. The annealed oligonucleotides were digested
with HindIII and SpeI and used to ligate into HindIII and
SpeI of pmir-Report luciferase (Ambion, Inc.). The oligonuc-
leotides used in these studies were mir 21,5 0-AATGCA-
CTAGTTCAACATCAGTCTGATAAGCTAGCTCAGCAA-
GCTTAATGC and 50-GCATTAAGCTTGCTGAGCTAGCT-
TATCAGACTGATGTTGAACTAGTGCATT; mir 19a,
50-AATGCACTAGTTCAGTTTTGCATAGATTTGCACA-
GCTCAGCAAGCTTAATGC and 50-GCATTAAGCTTGC-
TGAGCTGTGCAAATCTATGCAAAACTGAACTAGTG-
CATT; mir 23,5 0-AATGCACTAGTGGAAATCCCTGG-
CAATGTGATGCTCAGCAAGCTTAATGC and 50-GCAT-
TAAGCTTGCTGAGCATCACATTGCCAGGGATTTCCA-
CTAGT GCATT; mir15,5 0-AATGCACTAGTCACAAAC-
CATTATGTGCTGCTAGCTCAGCAAGCTTAATGC and
50-GCATTAAGCTTGCTGAGCTAGCAGCACATAATGG-
TTTGTGACTAGTGCATT; and mir 16,5 0-AATGCAC-
TAGTCGCCAATATTTACGTGCTGCTAGCTCAGCAAG-
CTTAATGC and 50-GCATTAAGCTTGCTGAGCTAG-
CAGCACGTAAATATTGGCGACTAGTGCATT. A BlpI
site (underlined) was added into each insert to test for pos-
itive clones.
Sequence of miRNA inhibitors
The sequences of the inhibitors used in our studies are listed in
the Supplementary Material and are the exact antisense copy
of the mature miRNA sequence that can be found in the
miRNA Registry (25), where all the nucleotides in the inhib-
itors contain 20-OMe modiﬁcations at every base and a 30 C3
containing amino linker.
Transfections
All transfections were carried out in triplicate. To transfect,we
diluted 5 pmol inhibitor into 10 ml Opti-Mem into each well.
We next diluted 0.3 ml NeoFx (Ambion, Inc.) into 10 ml Opti-
MEM for each sample, incubated for 10 min at room temper-
ature and added 10 ml of diluted transfection mixture to wells
that already contain the inhibitors and incubate for another
10 min at room temperature. We next added 100 ml of diluted
cell suspension mixture containing 8000 cells on top of the
complex.After24 h,the mediumwas changed andthe samples
were assayed after 72 h.
To transfect the miRNA inhibitors with reporter vectors, we
pre-plated 50–60 K HeLa cells 24 h prior to transfection in
24-well tissue culture plates. The next day  200 ng of each
vector (control and experimental vector) and 10–30 pmol
Nucleic Acids Research, 2005, Vol. 33, No. 4 1291inhibitor were diluted into 50 ml Opti-MEM into round-bottom
polystyrenetubes.Next,3mloflipofectamine2000wasdiluted
into 50 ml Opti-MEM and incubated at room temperature for
5min.ThedilutedDNA/inhibitorwasnextaddedintothetrans-
fection agent complex and incubated at room temperature for
20 min. The growth medium was changed and 100 mlo ft h e
complex was added to the cells. Twenty-four hours following
transfection reporter activity was measured.
Analysis of cell growth
To determine the number of HeLa cells remaining following
transfection with the miRNA inhibitors, we ﬁxed cells with
4% paraformaldehyde for 5 min 72 h post-transfection, per-
meablized with 0.1% Triton X-100 for 5 min and stained with
propidium iodide. The cells were next counted using the
Acumen Explorer (TTP LabTech). The relative number of
cells was normalized against a negative control inhibitor,
gapas, used in these experiments. To determine the number
of A549 cells remaining following transfection with the
miRNA inhibitors, we stained the cells using ViaCount
Flex Reagent and analyzed for cell number using the Guava
PCA-96 (Personal Cell Analysis). The relative cell numbers
obtained from the Guava instrument were also graphed and
normalized against a negative control miRNA inhibitor gapas
as described above. The negative control inhibitor used in
these experiments is the same sequence as a section of the
GAPDH mRNA and functionality inhibits GAPDH siRNA
activity (data not shown).
Caspase activity assay
The level of apoptosis in the transfected cells was determined
by measuring the induction of caspase-3 activity as follows.
First, the cells were washed once with phosphate-buffered
saline, lysed by adding 40 ml of cold lysis buffer (50 mM
HEPES, pH 7.2, 40 mM NaCl, 0.5% NP-40 and 0.5 mM
EDTA) to the wells and incubated for 20 min at 4 C. Half
the sample was used for analysis of caspase activity and the
other half was used for analysis of esterase activity that is
described below. To the half that was used for analysis of
caspase-3, 160 ml of buffer (50 mM HEPES, pH 7.4, 0.1%
Figure 1. (A) MiRNA reporter vectors used to analyze miRNA activity. The restriction sites for cloning the miRNA-binding sites are located in the 30-UTR of the
luciferasegeneinthepmir-Reportluciferasevector.OnceclonedthemiRNA-bindingsitevectorisco-transfectedwiththepmir-Reportb-galvectorasacontrolfor
transfectionefficiencyandamiRNAinhibitormoleculethatisspecifictothebindingsiteorismutatedascomparedwiththebindingsite.(B)Enhancedexpressionof
miRNA-regulated reporter by miRNA inhibitors. HeLa cells were plated at 50000 cells/well in 24-well plates. Cells were transfected using lipofectamine 2000 in
duplicatewithpmir-REPORTb-gal,aluciferasereporterconstructthatcontainedonetargetsiteforeithermiR-23,miR-21,miR-15a,miR-16ormiR-19aandeither
inhibitors for these miRNA or a negative control (NC). HeLa cells were also transfected with a control luciferase reporter vector lacking a miRNA-binding site
withoutaninhibitorto demonstratethe levelofactivitythatcanbe achieved foranunmodifiedpmir-REPORTluciferase.Twenty-fourhours post-transfectioncells
were assayed for luciferase and b-gal expression, and b-gal is used to normalize for differences in transfection efficiency.
1292 Nucleic Acids Research, 2005, Vol. 33, No. 4CHAPS, 0.1 mM EDTA and 10% sucrose) +5 mM DTT con-
taining 20 mM DEVDafc (ﬂuorogenic substrate N-acetyl-asp-
glu-val-asp-afc) substrate was added and ﬂuorescence was
measured at 400 nm/500 nm excitation/emission.
To normalize the caspase results, half of the samples were
also analyzed for esterase activity. First,the ﬂuorescein diacet-
ate (FDA) substrate (0.4 mg/ml FDA in acetonitrile) was
diluted 1:19 into dilution buffer (40 mM Tris–HCl, pH 7.5,
20 mM NaCl, 0.5% NP-40, 0.02 mg/ml ﬁnal concentration).
Samples were incubated for 10 min on ice, and 160 mlo f
diluted FDA substrate was added to each well. Fluorescence
was measured for 30 min using excitation of 488 nm and
emission of 529 nm.
RESULTS
Confirmation of miRNA inhibitor activity
To conﬁrm the activity of miRNA inhibitors, we constructed
reporter vectors that contained miRNA-binding sites for miR-
23, miR-21, miR-15a, miR-16 and miR-19a. These binding
sites were made by hybridizing oligonucleotides bearing the
miRNA-binding sites and cloning them into the HindIII and
SpeI sites of the pmir-REPORT luciferase vector (Figure 1A).
This places the miRNA-binding site directly into the 30-UTR
of the luciferase gene. We tested the activity of the miRNA
inhibitors by transfecting the luciferase reporter vector bearing
the miRNA-binding site with the miRNA inhibitor and the
pmir-Report b-gal vector (Figure 1A) as a control for trans-
fection efﬁciency. In addition, we transfected the luciferase
vectors bearing the miRNA-binding sites and b-gal vectors
with a negative control inhibitor that does not target any
cellular miRNA (gapas). Following transfection into HeLa
cells, both luciferase and b-gal activity were measured and
the relative level of luciferase was normalized against the
b-gal readings to control for transfection variation. In each
case, the miRNA inhibitors were effective at inhibiting the
ability of the endogenous miRNA to inhibit the expression of
the reporter gene containing the miRNA-binding site
(Figure 1B). This indicates that the miRNA inhibitors are
effective at inhibiting miRNA function. The extent of the
induction of luciferase activity is different for several inhib-
itors. We have found that many of these miRNAs are
expressed at varying levels in HeLa cells and this could be
what is accounting for the differential effects between inhib-
itors and reporter vectors (Supplementary Figure 2).
Identification of miRNA involved in cell growth
After validating the miRNA inhibitors, we produced a library
of over 90 miRNA inhibitors and screened for miRNAs that
were important for growth in the cervical cancer-derived cell
line, HeLa. In each well of a 96-well plate, an miRNA inhib-
itor targeting a different miRNA was transfected as described
in Materials and Methods. The cells were analyzed 72 h post-
transfection for cell number and the numbers obtained
were normalized to the negative control gapas inhibitor. We
identiﬁed a hit as anything that was 30% greater or less than
gapas. Each transfection was performed in triplicate, and the
standard deviations are represented on the graph shown in
Figure 2. Inhibitors that had error bars that were inside the
cutoff were not included as hits. Using these criteria, we
identiﬁed 19 miRNA that inhibited cell growth following
inhibition in HeLa cells (miR-95, 124, 125, 133, 134, 144,
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Figure 2. Identification of miRNAs that alter cell proliferation in HeLa cells. In 96-well plates, 8000 HeLa cells were reverse transfected with miRNA inhibitors
(5 pmol) in triplicates using Ambion siPORT Neo-FX. Seventy-two hours post-transfection, cells were fixed with 4% paraformaldehyde, permeablized with 0.1%
TritonX-100 and stained with propidium iodide to look at total cell number. The plates were scanned using the TTP LabTech Acumen Explorer.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1293150, 152, 187, 190, 191, 192, 193, 204, 211, 218, 220, 296 and
299) and 2 miRNA that had profound increases in cell growth
(miR-21 and miR-24).
In order to analyze whether the same miRNAs are involved
in cell growth in different cell lines, we transfected the library
of miRNA inhibitors into the lung carcinoma cell line, A549.
Following transfection and analysis of cell number, we used
the same criteria for a hit that was used above (30% above and
below the gapas control transfection). As shown in Figure 3,
9 miRNAs inhibitors that down-regulated cell growth
include miR-7, 19a, 23, 24, 134, 140, 150, 192 and 193
miRNAs, and 9 miRNA inhibitors that were found to
increase cell growth include miR-107, 132, 155, 181a,
191, 194, 203, 215 and 301. Among these 18 miRNAs,
miR-24, 134, 150, 191, 192 and 193 were also identiﬁed
in the HeLa screen, miR-24, inhibitors down-regulated growth
in A549 but increased cell growth in HeLa, while the other
miRNAs decreased cell growth in both A549 and HeLa cells.
These data demonstrate the complexity of the regulatory role
miRNA play in cell growth regulation between cells and is
discussed in further detail below.
Identification of miRNA involved in apoptosis
We next screened for miRNAs that were involved in apoptosis
in HeLa cells to identify correlations between hits that were
found to reduce/increase cell number with miRNAs that
reduced/increased relative amounts of apoptosis. To perform
this experiment, we transfected HeLa cells with the library of
miRNA inhibitors and analyzed the effects the inhibitors had
on the activation of caspase-3 activity. Activation is one
marker often used for analyzing the induction of apoptosis.
The amount of caspase activation was compared relative with
that observed with the negative control inhibitor molecule
(gapas). Any miRNA that changed caspase-3 activity greater
than or less than 30% compared with gapas was considered a
hit. In Figure 4, we found 7 miRNA that increased the level of
apoptosis (miR-1d, 7, 148, 204, 210, 216 and 296) and one
miRNA that decreased apoptosis (miR-214). This data suggest
that speciﬁc miRNAs are involved in the cell death response.
In order to analyze interactions between miRNA that inﬂu-
enced cell death in HeLa cells with those that inﬂuenced
apoptosis, we graphed the miRNA as a function of cell number
compared with caspase-3 activity. This representation of the
data quickly points out the hits that cause increases/decreases
in cell growth and increases/decreases in caspase activity
(Figure 5). In particular, miR-218 was found to inhibit cell
growth and induce apoptosis. Thus, for miR-218, growth
inhibition may be due to the induction of apoptosis. While
for miR-190, cell growth inhibition did not coincide with the
induction of apoptosis, suggesting that it may be inhibiting cell
growth through cell cycle arrest. These data further point out
the complexity of the regulatory circuitry of miRNA on
biological processes.
DISCUSSION
Reporter genes have been useful to conﬁrm predicted miRNA-
binding sites (19,20) making them a useful tool for the initial
analysis of potential miRNA-binding sites. However, without
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Figure 3. ScreenformiRNAinvolvedin cellviabilityin A549cells.In96-wellplates,8000HeLacellswerereversetransfectedwithmiRNAinhibitors(5pmol)in
triplicatesusingAmbionsiPORTNeo-FX.Seventy-twohourspost-transfection,cellsweretrypsinizedandtransferredtoanon-tissuecultureplate,sothatcellswould
not adhere. Cells were stained using ViaCount Flex Reagent and analyzed for total cell number using the Guava PCA-96 (Personal Cell Analysis).
1294 Nucleic Acids Research, 2005, Vol. 33, No. 4evidence to demonstrate that the endogenous miRNA is chan-
ging the expression of the endogenous gene, it is difﬁcult to
know whether these results are biologically relevant. This will
require that the antibody against the predicted products is
available and this is not always the case. Since predicted
miRNA targets are a good roadmap for possible targets, but
will not always be correct, we used miRNA-binding sites that
contain direct matches to the endogenous miRNA to ensure
that the miRNA will function on the reporter gene (21,24,26).
Since it has been shown that a miRNA can act like a siRNA
andcleavethemiRNAandtargetitfordegradation,webelieve
this is an effective approach to have taken to verify activity of
the miRNA inhibitors (27).
We synthesized over 90 miRNA inhibitors and used these to
screen for miRNAs that were involved in cell growth and
apoptosis processes that are among the widely studied gene
cell pathways and that have direct relevance to cancer and
development. In each assay, the relative cutoff for a hit was
made at 30% above and below the level observed for the
negative control inhibitor gapas. We could have been less
stringent and pulled out additional hits; however, making
this cutoff stringent allowed for the identiﬁcation of only
major differences in the biological activity of particular
miRNA. We also did not include hits that had standard
deviations that fell within the cutoff for a hit thus dropping
out additional hits. Although we are not counting many
miRNAs as hits due to our stringent cutoff does not mean
they are not biologically relevant. It is important to mention
that the miRNAs that were hits in our screens caused a pheno-
type by being inhibited. The miRNA may be mediating this
effect through increasing protein expression of their targets
that thenleadstochangesingrowthorapoptosis.Thus,itisthe
-20
0
20
40
60
80
100
120
140
160
180
200
A
v
g
.
 
N
T
m
i
r
1
d
m
i
r
7
m
i
r
9
m
i
r
1
0
a
m
i
r
1
5
a
m
i
r
1
6
m
i
r
1
8
m
i
r
1
9
a
m
i
r
2
0
m
i
r
2
1
m
i
r
2
2
m
i
r
2
3
m
i
r
2
4
m
i
r
2
5
m
i
r
2
6
a
m
i
r
2
7
a
m
i
r
2
8
m
i
r
3
0
a
m
i
r
3
2
m
i
r
3
4
m
i
r
9
2
m
i
r
9
3
m
i
r
9
5
m
i
r
9
6
m
i
r
9
8
m
i
r
9
9
m
i
r
1
0
0
m
i
r
1
0
1
-
1
m
i
r
1
0
3
m
i
r
1
0
7
m
i
r
1
2
4
m
i
r
1
2
5
a
m
i
r
1
2
7
m
i
r
1
2
6
m
i
r
1
2
8
m
i
r
1
2
9
m
i
r
1
3
2
m
i
r
1
3
3
m
i
r
1
2
4
m
i
r
1
3
6
m
i
r
1
3
7
m
i
r
1
4
0
m
i
r
1
4
1
m
i
r
1
4
3
m
i
r
1
4
4
m
i
r
1
4
6
m
i
r
1
4
8
m
i
r
1
4
9
m
i
r
1
5
2
m
i
r
1
5
0
m
i
r
1
5
4
m
i
r
1
5
5
m
i
r
1
8
1
a
m
i
r
1
8
2
m
i
r
1
8
3
m
i
r
1
8
4
m
i
r
1
8
6
m
i
r
1
8
7
m
i
r
1
8
8
m
i
r
1
9
0
m
i
r
1
9
1
m
i
r
1
9
2
m
i
r
1
9
3
m
i
r
1
9
4
m
i
r
1
9
5
m
i
r
1
9
6
m
i
r
1
9
9
a
m
i
r
2
0
3
m
i
r
2
0
4
m
i
r
2
0
5
m
i
r
2
0
6
m
i
r
2
0
8
m
i
r
2
1
0
m
i
r
2
1
1
m
i
r
2
1
2
m
i
r
2
1
4
m
i
r
2
1
5
m
i
r
2
1
6
m
i
r
2
1
8
m
i
r
2
1
9
m
i
r
2
2
0
m
i
r
2
2
1
m
i
r
2
2
3
m
i
r
2
2
4
m
i
r
2
9
6
m
i
r
2
9
9
m
i
r
3
0
1
m
i
r
3
0
2
m
i
r
3
2
0
m
i
r
3
2
1
l
e
t
7
a
l
e
t
7
c
L
e
t
7
g
G
a
p
A
S
m
i
r
1
2
2
a
N
o
r
m
a
l
i
z
e
d
 
C
a
s
p
a
s
e
 
F
l
u
o
r
e
s
c
e
n
c
e
Figure 4. Effects of miRNA inhibitors on caspase activity in HeLa. In 96-well plates, 8000 HeLa cells were reverse transfected with miRNA inhibitors (5 pmol) in
triplicates using Ambion siPORT Neo-FX. Seventy-two hours post-transfection, cells were analyzed for caspase and esterase activity as described in the Materials
and Methods. Esterase activity was used to normalize for differences in cell number that may exist owing to the miRNA inhibitor causing defects in cell growth.
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Figure 5. Effects of miRNA inhibitors on caspase activity compared with cell growth in HeLa cells. We graphed the data that were generated from Figures 2 and 4
together to compare hits that affected cell proliferation with those that affected apoptosis.
Nucleic Acids Research, 2005, Vol. 33, No. 4 1295gain of protein activity rather than the loss of protein activity
that is the possible mechanism involved. Knowing the targets
of the miRNA will yield important information about the
mechanism of regulation of these processes and how they
may be able to be ﬁne-tuned with the help of miRNAs.
We ﬁrst screened for miRNAs that inﬂuenced cell growth in
two different types of cancer-derived cell lines, HeLa
and A549 cells. From these experiments, we identiﬁed a
complexity of activity for miRNAs in these different cell
lines. For example, in HeLa, we found that inhibition of
miR-95, 124, 125, 133, 134, 144, 150, 152, 187, 190, 191,
192, 193, 204, 211, 218, 220, 296 and 299 caused a decrease in
cell growth and that inhibition of miR-21 and miR-24 had a
profound increase in cell growth. The miR-21 and 24 gene
deletions have been shown to be associated with chromosomal
deletion sites in cancers. Since the inhibition of these genes
was found to increase cell growth, it suggests that the expres-
sion of these two miRNA may be an important growth regu-
lator in cells (19). On the other hand, miR-7, 19a, 23, 24, 134,
140, 150, 192 and 193 down-regulated cell-growth and miR-
107, 132, 155, 181, 191, 194, 203, 215 and 301 increased cell
growth when inhibited in A549 cells. Common miRNAs that
decreased cell growth include miR-134, 192 and 193. There
were no common miRNAs that increased cell growth. MiR-24
increased cell growth in HeLa but was found to decrease cell
growth in A549, while miR-191 increased cell growth in A549
and decreased in HeLa. These differences observed between
the same miRNA in different cell lines suggest that the targets
of the miRNA may be different, the targets of the miRNA have
different activities, the miRNAs are differentially expressed or
duetodifferentialtransfectionefﬁciencyinthetwocells types.
We have ruled out different levels of transfection efﬁciency
between the two cells lines and have identiﬁed signiﬁcant
differences in expression proﬁles between A549 and HeLa
cells. Given this, one reason for observing the different
hits is due to different levels of expression (Supplementary
Figure 2). In addition, since no common miRNAs were found
to increase cell growth between the two cell lines, another
reason for observing different effects could still be due to
miRNA target differences. It should also be noted that
these are primary hits and require substantial downstream
validationtosortoutfalse-positivehitsthatmayhaveoccurred.
We also used screening to identify miRNAs involved in
induction or inhibition of steady state levels of apoptosis in
HeLa cells. For these studies, we identiﬁed miR-1d, 7, 148,
204, 210, 218, 296 and 381 as hits that increased the level of
apoptosis and miR-214 that decreased apoptosis. In another
case, miR-218 caused a decrease in cell growth in HeLa but its
inhibition increased the level of apoptosis, suggesting that
inhibition of miR-218 may be inhibiting cell growth by indu-
cing apoptosis. In other sets of hits, apoptosis was found
unchanged while cell growth either increased or decreased.
The majority of those that did have an effect on cell growth
but not apoptosis caused inhibition of growth, while only a
few hits in general caused increase in growth.
The availability of libraries of miRNA inhibitors as well as
methods for high-throughput delivery will make it possible to
identify miRNAs involved in any cellular process for which
there is a quantitative phenotypic assay. This will ultimately
lead not only to a greater understanding of the regulatory
mechanisms used to control cell processes but might also
reveal key pathways that might be exploited for disease
detection, prevention or treatment.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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